Treatment with intravenous immunoglobulin (IVIG) offers significant pain relief in patients with painful diabetic polyneuropathy (DPN) resistant to standard therapies, without deleterious side effects, according to the results of a trial.
Higher intake of plant-based fat, in particular n-6 polyunsaturated fatty acids (PUFAs), in place of carbohydrate during midlife was associated with a reduced risk of cognitive impairment in Chinese adults in later life, according to the Singapore Chinese Health Study (SCHS).
Use of lacosamide therapy in the long-term management of adult patients with epilepsy is effective and well tolerated, yielding seizure freedom rates comparable to that achieved with controlled‐release carbamazepine (carbamazepine‐CR), as reported in a recent study.
Three anticonvulsant drugs — levetiracetam, fosphenytoin, and valproate — are equally effective in stopping life-threatening epilepsy seizures in patients who are unresponsive to benzodiazepines, thus providing affirmation for physicians that any of the three drugs can be used for treating status epilepticus, according to results from ESETT*.
Asian ischaemic stroke patients with small and fragile cerebral vessels, as evidenced by the presence of multiple cerebral microbleeds (CMBs), may fare better with cilostazol than aspirin, as the former proves more effective at preventing cerebral haemorrhages especially when administered before white matter changes become extensive, according to the results of a subgroup analysis of the PICASSO* trial.
A prospective cohort study of mothers taking antiepileptic drugs (AEDs) and their breastfed infants has found substantially lower AED concentrations in infant vs maternal blood, with nearly half of all obtained AED concentrations in nursing infants being less than the lower limit of quantification (LLoQ).
New drug applications approved by US FDA as of 16 - 31 December 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Adults who developed multiple sclerosis (MS) in childhood or adolescence had significantly higher odds of impairment and greater decline over time in information-processing efficiency than adults who developed MS later in life, independent of age or disease duration, a large population-based longitudinal cohort study has shown.